Lenercept

Drug Profile

Lenercept

Alternative Names: p55TNFR-Ig; RO 452081; Tenefuse; TNFr IgG1; TNFR55 IgG1

Latest Information Update: 08 Apr 2004

Price : $50

At a glance

  • Originator Roche
  • Developer Genentech; Roche
  • Class Anti-inflammatories; Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Allergic asthma; Rheumatoid arthritis; Septic shock

Most Recent Events

  • 31 Dec 2002 Discontinued - Preclinical for Allergic asthma in USA (unspecified route)
  • 11 Jul 2000 A study has been added to the pharmacokinetics section
  • 20 Sep 1999 Discontinued-III for Septic shock in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top